Phase 2 Leukaemia Trial, Recruiting (NCT05863234)

Phase 2 Leukaemia Trial, Recruiting NCT05863234 Sponsor: Hiroshima University Hospital Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT05863234 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a condition called Aggressive Natural Killer-cell Leukaemia (ANKL), whether it is a new diagnosis or the disease has come back, based on internationally recognised diagnostic standards (WHO 2017 guidelines).

Who may not be able to join:

People whose doctors consider them well enough to receive chemotherapy as a treatment for their ANKL.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +81 82-257-5555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05863234

Sponsor: Hiroshima University Hospital

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: +81 82-257-5555

More information: https://clinicaltrials.gov/study/NCT05863234

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a condition called Aggressive Natural Killer-cell Leukaemia (ANKL), whether it is a new diagnosis or the disease has come back, based on internationally recognised diagnostic standards (WHO 2017 guidelines).

Who may not be able to join:

People whose doctors consider them well enough to receive chemotherapy as a treatment for their ANKL.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Hiroshima University Hospital

Registry

ClinicalTrials.gov

Start date

21 September 2023

Est. completion

31 March 2026

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Number of incidence of AEs and DLTs by PPMX-T003 repeated continuous intravenous administration (the first course)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov